ArticleCardiovascular diabetology2025
The mineralocorticoid receptor antagonist finerenone enhances cardiovascular recovery upon food intake normalization in obese mice.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Finerenone Beyond Diabetic Kidney Disease: Emerging Evidence and Potential Systemic Implications.Journal of clinical medicine · 2026Review
- Correction: The mineralocorticoid receptor antagonist finerenone enhances cardiovascular recovery upon food intake normalization in obese mice.Cardiovascular diabetology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with obesity exhibit high prevalence of heart failure with preserved or mildly reduced ejection fraction (HFpEF or HFmrEF). Recently, the mineralocorticoid receptor antagonist finerenone demonstrated benefits in this population. Glucagon-like peptide-1 analog aided weight loss also showed benefits. We hypothesized that finerenone would improve cardiovascular parameters when combined with weight loss in previously obese mice.
methodsMice were fed a high-fat diet (HFD) for 24 weeks, and were compared to mice fed a HFD for 16 weeks before returning to a standard diet for a further 8 weeks (rSD), with or without finerenone treatment 1 mg.kg
resultsAfter 16 weeks of HFD, compared to controls, obese mice had hyperglycaemia and insulin resistance, no difference in LV fractional shortening but increased LV filling pressure, impaired LV compliance, and reduced exercise capacity. After 24 weeks, this obesity phenotype was worsened by a reduction in MPR, LV fractional shortening, and cardiac output. After returning to standard diet, compared to the HFD group, body weight decreased in both the rSD and rSD + F groups, with improvements in glycaemia, insulin resistance, LV stroke volume, and LV compliance. In the rSD + F group, compared to rSD group, finerenone further improved LV compliance (34% improvement) (LVEDPVR: Ctl 1.19 ± 0.25, HFD 4.75 ± 0.31
conclusionIn the mouse model of HFD-induced obesity and heart failure, finerenone improves weight loss-induced recovery of cardiac function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.